{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"'A participant was considered ADA positive if baseline titer was missing or negative and participant had \\>=1 post-treatment positive titer, or positive titer at baseline and had a \\>=4-fold increase in titer from baseline in \\>=1 post-treatment sample.","groups":[{"description":"Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).","id":"OG000","title":"Elranatamab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Immunogenicity analysis set included all enrolled participants who received at least one dose of study treatment and had at least one sample tested for ADA.","reportingStatus":"POSTED","timeFrame":"From the date of first dose up to maximum of 65.1 weeks of treatment","title":"Number of Participants With Anti-drug Antibodies (ADA) of Elranatamab","type":"SECONDARY","unitOfMeasure":"Participants"}